02:03 , Jun 15, 2019 |  BioCentury  |  Politics, Policy & Law

Signs of hope on patent eligibility reform as Congress weighs arguments

The wait is still far from over for fixing the rules on what can be patented -- a move that could give diagnostics a fighting chance of becoming commercially viable. That said, a three-day Congressional...
01:39 , May 4, 2019 |  BioCentury  |  Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
19:48 , May 3, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 22 profitable biotechs and pharmas are slated to report earnings this week. (A) During trading hours in Europe; premarket on U.S. exchange; (B) Fiscal 4Q; Company Date Pre/post mkt 1Q19...
00:00 , Apr 26, 2019 |  BC Extra  |  Company News

Management tracks: Canbridge, Averum, WindMIL

Cancer and rare disease company Canbridge Pharmaceuticals Inc. (Beijing, China) hired Glenn Hassan as CFO and CBO and Gerald Cox as chief development strategist and interim CMO. Hassan, who was director, cross border healthcare investment...
22:34 , Apr 22, 2019 |  BC Extra  |  Company News

Management tracks: MeiraGTx, Retrophin, Aduro

MeiraGTx Holdings plc (NASDAQ:MGTX) said Katherine Breedis stepped down as CFO on April 16, a little over six months after she joined the gene therapy company. MeiraGTx said COO Richard Giroux will take on the...
22:48 , Mar 27, 2019 |  BC Extra  |  Company News

Management tracks: Epic, Axcella, KalVista

Lloyd Sanders will succeed Murali Prahalad as president and CEO of cancer diagnostic company Epic Sciences Inc. (San Diego, Calif.). Sanders was president of the oncology segment of molecular diagnostics company Myriad Genetics Inc. (NASDAQ:MYGN)....
02:44 , Feb 28, 2019 |  BC Week In Review  |  Clinical News

Lynparza notches first in POLO trial of pancreatic cancer

AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) announced the first positive data for a targeted agent in a molecularly defined subgroup of patients with metastatic pancreatic cancer. On Feb. 26, the...
23:05 , Feb 1, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 15 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 3Q; (B) Fiscal 2Q; (C) During trading hours in Europe; premarket on U.S. exchange Company Date...
23:40 , Jan 25, 2019 |  BioCentury  |  Politics, Policy & Law

101 problems with patent eligibility

The U.S. diagnostics industry is being strangled, and other life science inventions are being hobbled by, ill-conceived and contradictory patent policies. The USPTO director has signaled he wants to help, but only Congress has the...
21:11 , Dec 31, 2018 |  BC Extra  |  Company News

Management tracks: Myriad co-founder Meldrum passes away

Peter Meldrum, co-founder and former CEO of Myriad Genetics Inc. (NASDAQ:MYGN), passed away on Dec. 20 at the age of 71. Meldrum retired from the molecular diagnostics company in 2015, when Mark Capone became president...